Drugs / Elsubrutinib
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04451772 | Jul 2020 → Jan 2024 | systemic lupus erythematosus | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03978520 | Jul 2019 → Jan 2022 | systemic lupus erythematosus | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT03823378 | May 2019 → Sep 2020 | rheumatoid arthritis | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT03682705 | Oct 2018 → Mar 2020 | rheumatoid arthritis | AbbVie | Completed | Met primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-05-31 | AbbVie | Results Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus abbvie.com ↗ |
| 2023-03-23 | AbbVie | Results AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus Erythematosus abbvie.com ↗
No new safety signals were identified with upadacitinib, and a similar safety profile was observed for the combination therapy (ABBV-599) as for treatment with upadacitinib alone |
All press releases naming this drug 2 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elsubrutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03682705 ↗ |
| Known as | ABBV-105 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594348 ↗ |
| Action | Inhibit | “the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib” PMID 38293957 ↗ Apr 2022 |
| Modality | Small molecule | — CHEMBL4594348 ↗ |
| Route | Oral | “Elsubrutinib capsule will be administered orally.” NCT03682705 ↗ |
| Target | BTK | “the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib” PMID 38293957 ↗ Apr 2022 |